Clinical Research Studies
As an independent
facility, we work with a broad
spectrum of sponsors to assist each of them with their
clinical research. Our areas of investigation include
medical therapies for the prevention and/or treatment of
the following conditions:
Diabetes: Types 1 and 2
- Diabetic complications
- Thyroid disease
- Erectile disfunction
- Hormone deficiency in men and women
- Growth Hormone deficiency in children and adults
In addition, we have conducted studies on the
long term cardiovascular safety of various medications.
Our close association with subspecialists in other
medical fields has also provided opportunities to
participate in clinical studies involving such
conditions as depression and anxiety.
The sections below contain information about the wide
range of research in which we are involved at this time.
We are now interviewing individuals who are
interested in participating in one of the clinical
studies listed below. The health condition of a
potential participant must meet the criteria discussed
in the specific study description. During the research
period, all physical examinations, lab services and
study medications are provided free of charge.
Additionally, in certain studies, some of a
participant’s routine medication may be covered. In
diabetes studies, the cost of a glucose meter and test
strips may be covered as well. Most study sponsors also
offer a stipend to participants to help compensate for
To see the “Participant Questionnaire”,
If you have questions, please call our office at
- A comparative 12-week study of a new medication
for individuals with Type 2 diabetes currently being
treated with metformin. Participants must be between
the ages of 18 and 70 years and on a stable dose of
metformin. Participation will include 8 office
visits within a 14-month period. Physical exam, labs
and some supplies provided.
- A 26-week study evaluating a new, once daily,
oral diabetes treatment combined with insulin in
adults with Type 1 diabetes. This study requires 12
office visits. Physical exam, labs and some supplies
- A study to evaluate dapagliflozin as add-on
treatment to insulin therapy in adults (age 18-75)
with Type 1 diabetes. Participation will be
approximately 15 months with 23 study visits.
Physical exam, labs and some supplies provided.
- A comparative study evaluating efficacy and
health outcomes of Toujeo® (newly approved
long-acting insulin) compared to available basal
insulins. Adult participants must not have been
treated previously with insulin. Duration of the
study will be 1 year with 4-6 office visits.
Physical exam, labs and some supplies provided.
- A long-term study to determine the effect of
albiglutide (a GLP-1 medication) when added to
current diabetes treatment. Participants must have
Type 2 diabetes and be at least 18 years of age.
This study will last 3-5 years with approximately 20
office visits. Physical exams, labs and some
supplies provided. (HARMONY)
- A study examining the effectiveness of a new
cholesterol medication for reducing the occurrence
of major cardiovascular events (e.g. stroke, heart
attack or death related to these conditions). The
investigation focuses on high risk persons who have
had a stroke, heart attack or related condition
within the last 5 years. Participants must be at
least 18 years old and taking a “statin” medication
or be “statin” intolerant. (SPIRE)
- A study to investigate the long-term impact of
treatment with linagliptin in cardiovascular
morbidity, mortality and renal function in a
selected population of adult patients with Type 2
diabetes. Study participation could last up to 4
years. Physical exam, labs and some supplies
- A study comparing efficacy and safety of the
morning injection insulin (Toujeo®) versus Lantus®
in adults 18-70 years of age with Type 1 diabetes.
The duration of the trial is 20 weeks including
follow-up visits. There will be 8-10 regular office
visits during this time. Physical exam, labs and
some diabetes supplies provided. (EDITION JR)
- A 6-month study comparing a new glargine-like
insulin and Lantus® once daily in children and
adolescents with Type1 diabetes with a 6-month
extension period. Participants must be between ages
6-17 years, have had diabetes for at least 1 year
and not be using an insulin pump. Maximum duration
of participation is approximately 58 weeks. Physical
exam, labs and some supplies provided.
- A study comparing faster-acting insulin aspart,
with NovoRapid® both in combination with insulin
degludec in children and adolescents with Type 1
diabetes. Participants must be between the ages of
1-18 years. Weight must be at least 49.5 pounds.
Study duration will be approximately 44 weeks
including screening visits and follow-up visits.
There will be at least 16 office visits. Physical
exam, labs and some supplies provided. (Onset7)
- A study evaluating faster-acting insulin aspart
compared to NovoRapid® both in combination with
insulin degludec. Individuals with Type 1 diabetes
diagnosed at least one year ago and at least 18
years of age will be evaluated. Total duration of
participation is 41 weeks. Physical exam, labs and
some supplies provided. (Onset8)
- A devise study evaluating multiple daily
injections and continuous glucose monitoring (CGM)
in individuals with Type 1 and Type 2 diabetes.
- A study evaluating the safety and efficacy of a
new medication to preserve insulin production and
secretion in participants with new onset Type 1
diabetes ages 6-35.
- A study evaluating long-term treatment with
BELVIQ on the incidence of major adverse
cardiovascular events and conversion to Type 2
diabetes in obese and overweight patients with
cardiovascular disease. (CARMELLIA)
- A trial comparing cardiovascular safety of
insulin degludec versus insulin glargine in patients
with Type 2 diabetes with high risk of
cardiovascular events. (DEVOTE)
- A study to evaluate cardiovascular outcomes
during treatment with exenatide once-weekly in
patients with Type 2 diabetes (EXSCEL).
- A study to assess cardiovascular outcomes
following treatment with a new SGLT-2 class
medication in patients with Type 2 diabetes and
established vascular disease.
- A study to demonstrate the superiority of a new
medication as adjunct therapy for adults with Type 1
diabetes and inadequate glycemic control with
insulin therapy. There are two sub-studies involved
with a CGM device and/or DEXA scan included. (inTANDEM)
- Two trials assessing efficacy, long-term safety
and tolerability of a PCSK9 inhibitor for treatment
in subjects with hyperlipidemia or mixed
- An open label one-year study comparing Mylan’s
glargine-like insulin with Lantus® in patients with
Type 1 diabetes with a possible 52-week extension
- Amgen: An open-label extension study to assess
the long-term safety and efficacy of a PCSK9
inhibitor for treatment of hypercholesterolemia.
- A study evaluating the glycemic effects, safety
and tolerability of Metformin Delayed Release in
participants with Type 2 diabetes.
- A phase 4 study to evaluate Toujeo® and Tresiba
in individuals with Type 2 diabetes who are not on
- A phase 3a trial investigating the
cardiovascular safety of oral semaglutide in persons
with Type 2 diabetes. (PIONEER 6)
- A phase 3b study to evaluate a continuous
subcutaneous insulin infusion of faster-acting
insulin compared to NovoRapid® in adults with Type 2
- A phase 3b open label study focusing on patients
taking metformin. Compares the effectiveness of
combination of metformin with exenatide (delivered
by a small device inserted into the skin of the
abdomen) to combination with empagloflozin and with
- A phase 2a study to determine if golimumab can
preserve β-cell function in children and young
adults with newly diagnosed Type 1 Diabetes.